This clinical trial is focused on studying a condition known as Chronic Lung Disease, which often affects extremely premature babies. The study is evaluating a new treatment called Mecasermin rinfabate, also known by its code name OHB-607. This treatment is a solution given through an infusion, which means it is delivered directly into the bloodstream. The purpose of the study is to see if this new treatment can help prevent a specific type of lung disease in premature babies, known as Bronchopulmonary Dysplasia, which is a common cause of long-term lung problems in these infants.

The study will compare the effects of OHB-607 with the standard care that is usually given to premature babies. Participants in the study will be randomly assigned to receive either the new treatment or the standard care. The study will monitor the babies’ health and development over a period of time to see if the new treatment is safe and effective. The researchers will look at how many babies develop severe lung disease or other complications, and they will also track the overall health and growth of the babies involved in the study.

Throughout the study, the health of the babies will be closely monitored by healthcare professionals. The study aims to provide valuable information on whether OHB-607 can reduce the risk of severe lung disease in extremely premature infants, potentially leading to better outcomes for these vulnerable patients. The study will continue to gather data until the babies reach a certain age, ensuring a comprehensive understanding of the treatment’s impact.